NCT06220630

Brief Summary

The goal of this observational study is to investigate the features in Chinese male breast cancer (MBC) patients. The main question it aims to answer is:

  • The characteristics, treatment patterns and prognosis of Chinese MBC patients. The clinicopathological characteristics, treatment information and follow-up data of participants will be extracted from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved Chinese centers. Researchers will investigate the features, survival associated factors and other relevant factors of this population.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2021

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

January 13, 2024

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 24, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

January 24, 2024

Status Verified

January 1, 2024

Enrollment Period

4 years

First QC Date

January 13, 2024

Last Update Submit

January 13, 2024

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    The duration between the date of the first pathologic diagnosis and death from any cause or last follow-up.

    From the time of diagnosis to August 1, 2024 (anticipated).

Study Arms (1)

Chinese

About 1,200 Chinese male breast cancer cases are anticipated to collected retrospectively. The clinicopathological characteristics, treatment and survival information are retrospectively collected.

Other: Breast cancer

Interventions

Breast cancerOTHER

Male patients who were microscopically diagnosed as primary breast cancer.

Chinese

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All eligible cases were collected from a Chinese national database (Chinese Society of Clinical Oncology Breast Cancer database) and other involved centers.

You may qualify if:

  • Biological sex is male;
  • Microscopically diagnosed as primary breast cancer.

You may not qualify if:

  • Presence of skin-origin malignancy on the breast.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First affiliated hospital of Sun Yat-sen university

Guangzhou, Guangdong, 510030, China

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Ying Lin, MD, PhD

    1st affiliated hospital of Sun Yat-sen university

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Yuxuan Gao, MD

CONTACT

+86 18142846375gaoyx9@mail2.sysu.edu.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

January 13, 2024

First Posted

January 24, 2024

Study Start

August 1, 2021

Primary Completion

August 1, 2025

Study Completion

December 31, 2025

Last Updated

January 24, 2024

Record last verified: 2024-01

Data Sharing

IPD Sharing
Will not share

A part of Chinese data that support the findings of this study are available from Chinese Society of Clinical Oncology Breast Cancer Database but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Chinese data are however available from the corresponding author upon reasonable request and with permission of Chinese Society of Clinical Oncology Breast Cancer Database.

Locations

CN(1)